Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 420 publications
Cardiac Adverse Events Associated With Elotuzumab: A Disproportionality Analysis Using FDA Adverse Event Reporting System.
Journal: The Annals of pharmacotherapy
Published: August 04, 2025
Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series.
Journal: Hematology (Amsterdam, Netherlands)
Published: June 18, 2025
Using bispecific antibodies in a patient with peritoneal dialysis for relapsed multiple myeloma.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: May 13, 2025
Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system.
Journal: Expert opinion on drug safety
Published: April 30, 2025
Treatment Patterns, Goals, and Decision-Making Criteria for Second- and Third-Line Therapies for Multiple Myeloma in Germany.
Journal: Advances in therapy
Published: March 12, 2025
The efficacy of new drug regimens in treating newly diagnosed high-risk cytogenetic multiple myeloma patients: a systematic literature review and meta-analysis.
Journal: Frontiers in medicine
Published: February 13, 2025
Correction to Elotuzumab Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended Follow-Up of a Multicenter, Retrospective Real-World Experience With 321 Cases Outside of Controlled Clinical Trials.
Journal: Hematological oncology
Published: January 23, 2025
Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ Involvement.
Journal: American journal of hematology
Published: January 21, 2025
The multifaceted role of CS1 (SLAMF7) in immunoregulation: Implications for cancer therapy and autoimmune disorders.
Journal: Experimental cell research
Published: January 21, 2025
Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System.
Journal: European journal of clinical pharmacology
Published: January 13, 2025
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 13, 2024
Last Updated: 10/31/2025